CompletedNot applicableNCT00579683

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

The purpose of this study is to try to learn more about how small molecule kinase inhibitors work in treating lung cancer. Some early studies have shown that gefitinib, erlotinib and similar drugs are more likely to work if a particular DNA change (also known as a mutation) is found in a protein that is important in lung cancer. This protein is called the epidermal growth factor receptor (EGFR). Since small molecule kinase inhibitors sometimes stop working, we would like to examine your tumor to learn why these medicines are not working as well. Your tumor will be examined for a variety of things including changes in the DNA of the EGFR. We will also sequence parts of the genes for HER2, HER3, HER4, and KRAS, other proteins thought to be important in lung cancer.

Checked against the public recordLast updated Feb 4, 2016 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations5
SponsorMemorial Sloan Kettering Cancer Center
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Other: Tumor core biopsy for RNA isolation
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: Patients diagnosed with unresectable or metastatic non-small cell lung cancer (NSCLC) and who fulfill the following eligibility criteria will be considered eligible for this study. * Patient must have previously received treatment with small molecule kinase inhibitors targeting at least, in part, EGFR patients may have received other treatments since treatment with small molecule kinase inhibitors including radiation or chemotherapy) * Development of disease progression while actively receiving tyrosine kinase inhibitor * Signed informed consent Exclusion Criteria: * None

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memoral Sloan Kettering Cancer CenterBasking Ridge, New Jersey
  • Memorial Sloan-Kettering Cancer Center @ SuffolkCommack, New York
  • Memorial Sloan Kettering Cancer CenterNew York, New York
  • Memorial Sloan-Kettering at Mercy Medical CenterRockville Centre, New York
  • Memoral Sloan Kettering Cancer Center at PhelpsSleepy Hollow, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 4, 2016. Always confirm current availability with the study team.

View original record ↗